Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients
Source: OncLive, June 2021
Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial (NCT02362594) and crossed over to receive pembrolizumab (Keytruda; n = 155) post-recurrence derived a 38.8% overall response rate (ORR) and a 32% overall 3-year progression-free survival (PFS) rate, according to updated data that were presented during the 2021 ASCO Annual Meeting.1
